ArticleBlood cancer journal2025

Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.

Luis E Aguirre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.